RxDoctor Payments Data

Kamran Shaikh, MD

Cardiovascular Disease · Kyle, TXNPI 1457562274

Payments from drug & device makers

$96,131in general payments, 2019–2025

Across 206 payments — averaging $466.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lantheus Medical Imaging, Inc.$68K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$24K
  • Abbott$683
  • Inari Medical, Inc.$491
  • Johnson & Johnson$446
  • Impulse Dynamics (USA) Inc.$360
  • plus $2K from 18 others

What the payments were for

  • Consulting fees$250%
  • Speaking & faculty fees$79,75083%
  • Travel & lodging$8,5359%
  • Food & beverage$7,5218%
  • Entertainment$3000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$96,131 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$184,995
Medicare patients
650
Services billed
2,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban312$323,628
XareltoRivaroxaban131$168,560
EntrestoSacubitril/Valsartan115$144,442
Repatha SureclickEvolocumab50$44,363
Atorvastatin Calcium715$6,436
Carvedilol555$5,481
Losartan Potassium356$4,093
Amlodipine Besylate432$2,952
Lisinopril301$2,293
Prasugrel Hcl16$2,278
Flecainide Acetate50$2,084
Ranolazine ErRanolazine17$2,041
Rosuvastatin Calcium107$1,367
Amiodarone Hcl66$1,231
Pravastatin Sodium60$1,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$323,628312 claims
Johnson & JohnsonXarelto$446$168,560131 claims
NovartisEntresto$39$144,442115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Kyle

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →